Secondary dyslipidemia: its treatments and association with atherosclerosis

被引:37
|
作者
Yanai, Hidekatsu [1 ]
Yoshida, Hiroshi [2 ]
机构
[1] Kohnodai Hosp, Dept Diabet Endocrinol & Metab, Natl Ctr Global Hlth & Med, 1-7-1 Kohnodai, Chiba 2728516, Japan
[2] Jikei Univ, Dept Lab Med, Kashiwa Hosp, Chiba, Japan
来源
GLOBAL HEALTH & MEDICINE | 2021年 / 3卷 / 01期
关键词
hypothyroidism; low-density lipoprotein; nephrotic syndrome; triglyceride;
D O I
10.35772/ghm.2020.01078
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Dyslipidemia is classified into primary and secondary types. Primary dyslipidemia is basically inherited and caused by single or multiple gene mutations that result in either overproduction or defective clearance of triglycerides and cholesterol. Secondary dyslipidemia is caused by unhealthy lifestyle factors and acquired medical conditions, including underlying diseases and applied drugs. Secondary dyslipidemia accounts for approximately 30-40% of all dyslipidemia. Secondary dyslipidemia should be treated by finding and addressing its causative diseases or drugs. For example, treatment of secondary dyslipidemia, such as hyperlipidemia due to hypothyroidism, by using statin without controlling hypothyroidism, may lead to myopathy and serious adverse events such as rhabdomyolysis. Differential diagnosis of secondary dyslipidemia is very important for safe and effective treatment. Here, we describe an overview about diseases and drugs that interfere with lipid metabolism leading to secondary dyslipidemia. Further, we show the association of each secondary dyslipidemia with atherosclerosis and the treatments for such dyslipidemia.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 50 条
  • [21] Dyslipidemia and its Association with Meibomian Gland Dysfunction: A Systematic Review
    Kuriakose, Robin K.
    Braich, Puneet S.
    INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (04) : 1809 - 1816
  • [22] DYSLIPIDEMIA AND ATHEROSCLEROSIS - A FORECAST OF PHARMACEUTICAL APPROACHES
    GOTTO, AM
    CIRCULATION, 1993, 87 (04) : 54 - 59
  • [23] Establishment of an Atherosclerosis and Dyslipidemia Program in Kazakhstan
    Bekbossynova, Makhabbat
    Ivanova-Razumova, Tatiana
    Ablayeva, Ayana
    Oralbekova, Zhansaya
    MAYO CLINIC PROCEEDINGS, 2024, 99 (11) : 1698 - 1701
  • [24] Update on medical management of dyslipidemia and atherosclerosis
    Ginter, E.
    Simko, V
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2013, 114 (05): : 262 - 268
  • [25] DYSLIPIDEMIA AND THE CLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN THE ELDERLY
    Sujayeva, V.
    Kravchenko, G.
    ATHEROSCLEROSIS, 2022, 355 : E277 - E277
  • [26] PLASMA SORTILIN LEVEL AND ITS ASSOCIATION WITH ATHEROSCLEROSIS
    Oh, Tae Jung
    Ahn, Chang Ho
    Kim, Kyoung Min
    Moon, Jae Hoon
    Lim, Soo
    Park, Kyong Soo
    Jang, Hak Chul
    Choi, Sung Hee
    JOURNAL OF HYPERTENSION, 2016, 34 : E517 - E517
  • [27] Apolipoprotein CIII Links Dyslipidemia with Atherosclerosis
    Kawakami, Akio
    Yoshida, Masayuki
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2009, 16 (01) : 6 - 11
  • [28] The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis
    Hurtubise, Jessica
    McLellan, Krystie
    Durr, Kevin
    Onasanya, Oluwadara
    Nwabuko, Daniel
    Ndisang, Joseph Fomusi
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (12)
  • [29] The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis
    Jessica Hurtubise
    Krystie McLellan
    Kevin Durr
    Oluwadara Onasanya
    Daniel Nwabuko
    Joseph Fomusi Ndisang
    Current Atherosclerosis Reports, 2016, 18
  • [30] Novel molecules targeting dyslipidemia and atherosclerosis
    Tavridou, A.
    Manolopoulos, V. G.
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (08) : 792 - 802